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ABSTRACT. The adenosine deaminase G22A polymorphism 
(20q.11.33) affects the level of adenosine deaminase (ADA) expression, 
which plays an important role in the regulation of intracellular and 
extracellular concentrations of adenosine.  Recent studies reported 
greater ADA activity in diabetic patients and showed the role of ADA in 
the modulation of insulin activity and glucose homeostasis. We 
investigated whether the G22A polymorphism of the ADA gene is 
associated with type 2 diabetes mellitus (T2DM) in the Palestinian 
population and assessed the relationship between the G22A variant and 
fasting plasma glucose (FPG), glycated hemoglobin (HbA1c) and lipid 
profile among T2DM patients.  A total of 231 individuals with T2DM 
and a control sample of 101 non-diabetic participants were randomly 
selected from those who were attending United Nations Relief and 
Works Agency (UNRWA) clinics for treatment and/or follow up.  
Genomic DNA was extracted from peripheral blood samples and PCR-
RFLP was performed to identify the TaqI polymorphism G22A of the 
ADA gene. No significant differences were observed in the genotype and 
allele frequencies between T2DM patients and the control group. Yet, 
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among diabetic patients, the GG genotype was significantly associated 
with higher FPG and HbA1c when compared to the GA+AA genotype 
but had no influence on blood pressure, BMI or other metabolic 
parameters. In conclusion, we confirm that the GG genotype of the ADA 
gene is associated with poor glycemic control in T2DM Palestinians and 
points to the association of the G22A variant with decreased activity of 
the ADA enzyme, which is of paramount importance in the 
pathophysiology of T2DM. 
 
Key words: Diabetes Mellitus Type 2; Fasting Plasma glucose; Adenosine 
Deaminase; Glycated Hemoglobin; Palestine 
INTRODUCTION 
 
Type 2 Diabetes Mellitus (T2DM) is a progressive condition resulting from insulin 
resistance and /or from a reduction in insulin production by the pancreas (Gow et al., 2016). 
Its prevalence is increasing rapidly in middle- and low-income countries including 
Palestine. The prevalence of diabetes in the Palestinian population was 15.3% in 2010, but 
estimates have predicted it to rise to 20.8% by 2020 (Abu-Rmeileh, 2012; Abu-Rmeileh et 
al., 2013). The number of new cases in Palestine reported annually, has ranged from 150 to 
220 per 100,000 population, among which 95% of diabetic cases were diagnosed with 
T2DM (WHO,  http://www.emro.who.int/pse/palestine-news). Diabetes mellitus is 
strongly associated with lifestyle, genetic and family related risk factors. Immunological 
disturbance in T2DM subjects has been attributed to cell-mediated immunity and 
inappropriate T-lymphocyte function (Prakash et al., 2006). 
Adenosine deaminase (ADA), encoded by the ADA gene (gene map locus 
20q13.11), is an enzyme that catalyzes irreversible deamination of adenosine to inosine and 
has a crucial role in regulating extracellular and intracellular adenosine concentration 
(Franco et al., 2007a; 2007b; Concetti et al., 2015). ADA is widely distributed in most 
mammalian tissues, but the highest activity is observed in lymphoid and fatty tissues 
(Niedzwicki and Abernethy, 1991; Husseini et al., 2009). High lymphocytic ADA activity 
is associated with alteration in the cell-mediated immune response; altered  blood levels of 
this enzyme may predict immunological dysfunction associated with T2DM (Prakash et al., 
2006). The action of adenosine on glucose and lipid metabolism in adipose tissue is similar 
to that of insulin (Johansson et al., 2008). Adenosine has antilipolysis activity in adipose 
tissue and acts directly to stimulate insulin activity by increasing accessibility of glucose 
transporter type 4 (GLUT4) to the cell surface for glucose transportation (Antonioli et al., 
2014; Larijani et al., 2016), while it counteracts insulin action in the liver by activating A2B 
receptors (Yasuda et al., 2003; Antonioli et al., 2014). Han et al. (1998) demonstrated that 
blocking the action of adenosine with antagonists decreases transport of glucose to the 
skeletal muscles. Furthermore, it was reported that adenosine affects plasma levels of 
cholesterol and triglycerides by controlling liver cholesterol synthesis and thus the amount 
of fat tissue (Koupenova and Ravid, 2013). Several studies reported greater ADA activity in 
T2DM patients (Pinnelli, 2006; Khemka et al., 2013). High ADA levels result in an increase 
in serum TG levels in patients with T2DM by increasing lipolysis (Kaur et al., 2016). 
Prakash and Ananda Rao (2006) have demonstrated that elevated ADA activity is an 
important indicator of the immuno-pathogenesis of T2DM. Therefore, targeting adenosine 
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receptors has become promising in prophylaxis against diabetes and cardiovascular 
diseases.  
Because the level of endogenous adenosine is affected by the enzyme ADA, 
polymorphisms within the ADA gene may have some effect on ADA activity. It is reported 
that the common ADA variant G22A polymorphism (c.22G>A, rs73598374) decreases the 
rate of conversion of adenosine to inosine in cells by approximately 20-35%, leading to a 
buildup of adenosine (Battistuzzi et al., 1981). Therefore, it is hypothesized that individuals 
with the A allele show reduced ADA enzymatic activity and higher levels of both 
circulating and intracellular adenosine compared to homozygous GG individuals (Riksen et 
al., 2008).  
We investigated a possible association between ADA variant G22A with risk of 
T2DM. We also assessed the relationship between the G22A variant and fasting plasma 
glucose, glycated hemoglobin and lipid profile among type 2 diabetic Palestinians. 
MATERIAL AND METHODS 
Ethical considerations 
 
This study was approved by the Research Ethics Committee of Al-Quds University 
(Rf no. 2/SRC/4). Each participant signed a consent form after providing information about 
the study objectives. 
Study participants 
 
A total of 332 participants were enrolled in this study. All participants were 
unrelated, aged >40 years and recruited within the period of 2016-2017 in collaboration 
with UNRWA (United Nations Relief and Works Agency) clinics (Hebron and Ramallah, 
Palestine). All cases (n=231) were diagnosed with diabetes mellitus type 2 and were on use 
of oral hypoglycemic agents. Subjects on insulin treatment were excluded from the study. 
The control group (n=101) was selected from healthy individuals who came to the same 
clinic for an annual heath check-up with no history of DM, and their fasting plasma glucose 
concentration was ≤100 mg/dl, fasting total cholesterol<220 mg/dl and BMI <30 kg/m. 
Genomic DNA extraction and ADA genotyping 
 
A 5-mL sample of blood was taken from each participant via venipuncture into 
vacuum tubes with ethylenediaminetetraacetic acid (EDTA) for genomic DNA extraction 
using a commercial kit (QIAGEN GmbH, Hilden, Germany). To characterize the G22A 
polymorphism of the ADA gene, a partial fragment (397 bp) was amplified using a 
published primer pair (Safranow et al., 2007). The amplified product was digested using 
Taq I restriction enzyme (Nunes et al., 2011) generating two bands (152, 245 bp) for the 
GG genotype, three bands (397, 245, 152 bp) for the GA genotype and one band of 397 bp 
for the AA genotype, indicating absence of a Taq I restriction site. All PCR-RFLP products 
were analyzed using 2% agarose gel electrophoresis in TAE (Tris-acetate EDTA) buffer. 
 













All data were analyzed using SPSS software (IBM Corp. Released 2013. IBM SPSS 
Statistics for Windows, Version 23.0. Armonk, NY: IBM Corp.). The chi-square test was 
used to compare allelic and genotypic frequencies of the ADA gene. Comparison of 
biochemical and anthropometric parameters between groups was conducted using a one-
way ANOVA. Statistical significance was defined as P<0.05. 
RESULTS   
 
The anthropometrical and biochemical parameters of the study participants (231 
diabetic and 101 controls) are shown in Table 1.  Significant differences in anthropometrical 
and biochemical parameters were observed between the two groups (P<0.05). Among the 
diabetic group, 14.3, 9.5, 6.9 and 5.6% had cardio vascular disease (CVD), nephropathy, 
diabetic foot and retinopathy, respectively. Only 5.6% had normal BMI; 32.9% were 
overweight and 61.5%, were obese.  
 
Table 1. Anthropometrical and biochemical parameters of the diabetes study groups. Data are in means ± SD. 
BMI: Body mass index; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; FPG: Fasting plasma 
glucose; TC: Total cholesterol. 
    Parameters cases (n=231) controls (n=101) P-value 
Sex (M/F) 119:112 53:48 - 
Age at diagnosis (years) 50.9±9.9 NA - 
Age at sampling (years) 59.3 ±10.9 47.7±11.0 0.0001 
BMI (Kg/m2) 32.5±6.4 27.3±5.7 0.0001 
SBP (mmHg) 136.1±16.2 121.3±10 0.0001 
DBP (mmHg) 79.6±9.9.3 77.2±8.5 0.0001 
FPG (mg/dl) 162.3±58.5 85.2±8.7 0.0001 
TC (mg/dl) 184.3±45.6 168.4±33.8 0.0018 
NA: Not applicable 
Frequency distribution of ADA genotypes  
 
The frequencies of ADA genotypes were in Hardy–Weinberg equilibrium for 
patients and controls (p>0.05). Table 2 shows the allelic and genotypic frequencies of the 
G22A ADA gene polymorphisms in T2DM cases and controls. The frequency of the GG 
genotype was higher in both groups; however, the difference was not significant (p=0.6). 
 
Table 2. ADA genotype and allele frequencies in type-2 diabetes (T2DM) patients and controls 
Genotype T2DM (N=231) % Controls (N=101) % 
GG 66.7 69.3 
GA 30.7 28.7 
AA 2.6 2.0 
MAF (%) 18 16  
MAF: Minor allele frequency 
Association of ADA genotypes with anthropometrical and biochemical 
measurements  
 
As the frequency of the AA genotype in both groups was low, the GA and AA 
genotype carriers were grouped together in the analyses.  The mean of biochemical 
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characteristics in carriers of GG genotype and carriers of at least one A allele (GA+AA 
genotypes) are shown in Table 3. In the diabetic group, GG carriers had significantly higher 
fasting plasma glucose (FPG) (P=0.026) and higher HbA1c (P=0.037) when compared with 
GA+AA genotypes. On the other hand, the mean serum levels of TG, TC, LDL and HDL 
showed no significant  differences in GG carriers compared to GA+AA genotypes  
(P>0.05). Moreover, no association was found between the ADA genotype and cardio 
vascular disease or diabetes complications (P>0.05). 
In the control group, there was no evidence of an association of ADA genotypes 
with FPG (85.5±8.9 for GG and 84.5±8.0 for GA+AA, P=0.64) or with serum cholesterol 
(TC) (165.8±33.3 for GG and 177.7±35.2 for GA+AA, P=0.14). As the measurements of 
TG, LDL, HDL and HBA1c were not available for the control group, we could not 
demonstrate the effect of ADA genotypes on these biochemical parameters.   Both groups 
(cases and controls) showed no significant differences between the ADA genotypes and sex, 
age, BMI, as well as systolic and diastolic blood pressure.  
 
Table 3. Demographic characteristics and biochemical measurements across ADA genotypes in type 2 diabetes 
mellitus (T2DM) patients in the Palestinian population. BMI: Body mass index; SBP: Systolic blood pressure; 
DBP: Diastolic blood pressure; FPG: Fasting plasma glucose;   TC: Total cholesterol; TG: Triglyceride; HDL-C, 
high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol 
Values are presented as mean ± standard deviation; P value was obtained by one way ANOVA, P<0.05 was 
considered significant. NS: Not significant. 
DISCUSSION 
 
To the best of our knowledge, this study is the first to evaluate G22A ADA 
(rs73598374) in T2DM patients in Palestine. The G22A polymorphism of the ADA gene is 
reported to be the only known polymorphism that affects the expression of ADA levels 
(Hirschhorn et al., 1994). In our study, the control group was restricted to those aged >40 
years at the time of sampling to minimize misclassification given that they may develop 
diabetes later in their lives. Moreover, we excluded individuals with related traits of T2DM 
risk (obesity and hyperlipidemia) and/or had a family history of diabetes in first-degree 
relatives. 
Our study revealed that the GG genotype is the most common genotype in both the 
control and the patient groups, which was also found in other studies (Domingos et al., 
2014; Salehabadi et al., 2016). 
However, the overall A allele frequency of the ADA gene in our study participants 
was much higher than reported in Brazilian, Polish, Chinese and Iranian populations (Liu et 
al., 2006; Safranow et al., 2007; Domingos et al., 2014). Studies enlightening the 
               T2DM (n=231)     
  GG GA+AA P-value* 
Number 154 77 
Age(years) 59.8±10.5 58.4±11.9 NS 
Age at diagnosis (years) 50.9±9.6 50.7±10.7 NS 
BMI (kg/m2) 32.5±6.3 32.6±6.7 NS 
SBP (mmHg) 135.2±15.7 137.9±17.2 NS 
DBP (mmHg) 81.3±8.7 78.9±9.6 NS 
FPG (mg/dl) 168.4±63.8 150.3±44.2 0.026 
HbA1c 8.3±1.97 7.76±1.80 0.037 
TG (mg/dl) 177.6±127.9 181±127.8 NS 
TC (mg/dl) 185.3±47.4 182.5±42 NS 
HDL-C(mg/dl) 42.3±10.6 40.8±9.8 NS 
LDL-C(mg/dl) 107.1±24.3 104.2±24.7 NS 
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importance of the ADA gene in the medical field and its clinical implications among Arab 
population are rare. A recent study, conducted on Egyptian women, evaluated the 
association of ADA G22A gene polymorphism with recurrent spontaneous abortion (RSA) 
(Farhan et al., 2017). In that study there was no significant difference in allelic frequency of 
ADA G22A gene polymorphism among RSA patients as regards the co-morbidities, 
including diabetes (Farhan et al., 2017).To our knowledge, no data on allele and genotype 
frequencies of this polymorphism among diabetic patients have been reported in the Arab 
population. 
In agreement with earlier published studies (Domingos et al., 2014; Takhshid et al., 
2015), our results revealed no significant difference in allelic and genotypic frequency 
between the study groups (P>0.05), thus indicating no association of ADA G22A 
polymorphism with risk of T2DM in Palestinians. Yet, our study demonstrated that GG 
carriers had a significantly higher FPG (P=0.026) and higher HbA1c (P=0.037) compared to 
those who had at least one minor allele (GA+AA).These findings support the hypothesis 
that ADA G22A gene polymorphism leads to a reduction in ADA enzyme activity in 
diabetic patients and consequently increases intracellular concentration of adenosine, 
thereby attenuating pathologic consequences of T2DM. Interestingly, similar results have 
been demonstrated in gestational diabetes among Iranian women (Takhshid et al., 2015).  
However, as T2DM is a multifactorial disease, the effect of a single nucleotide 
polymorphism on the pathogenesis of T2DM should be considered with other lifestyle, 
genetic and environmental risk factors. It should be noted that no association between FPG 
level and ADA genotypes in the control group. Therefore, further studies with larger sample 
size and greater statistical power are required to verify these findings. 
 Several studies reported that ADA activity is positively correlated with blood 
glucose levels and HbA1c, which is an important indicator of long-term glycemic control 
(Lee et al., 2011; Siddiq et al, 2011; Dasegowda, 2015; Sapkota et al., 2017). Further, it was 
shown that ADA G22A gene polymorphism leads to a 30% reduction in ADA enzyme 
activity and thus carriers of the GA and AA genotypes of the ADA gene had higher 
concentrations of adenosine, greater activity of its receptors and less tolerance to glucose 
compared to those with the GG genotype (Xu et al., 1998; Chen et al., 2013; Concetti et al., 
2015).   
  On the other hand, the increase in ADA activity, and thus the decreased level of 
endogenous adenosine, resulted in an increase in lipolytic activity. Therefore, T2DM 
patients with elevated ADA levels may have hyperlipidemia due to increasing lipolysis 
(Kaur et al., 2016). Case control studies conducted by Kurtul et al. (2004; 2006) 
demonstrated that ADA activity was significantly increased in the serum of obese compared 
with non-obese subjects. In contrast, no significant difference was found in ADA activities 
between obese and non-obese Nepalese subjects with diabetes (Spakota et al., 2017). 
Another study showed a significant positive correlation between serum ADA level and FPG 
level among nonobese T2DM subjects, but no significant correlation in controls (Khemka et 
al., 2013). Moreover,   a previous study (Dasegowda et al., 2015) showed a significant 
positive correlation between ADA level and serum TG, TC and LDL cholesterol, whereas a 
negative correlation between ADA with HDL cholesterol levels was observed. In our study, 
we could not demonstrate an effect of the ADA variant on several traits that are associated 
with obesity and/or insulin resistant syndrome, such as BMI, blood pressure, and serum TG, 
TC, HDL and LDL cholesterol among the study subjects.   
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Dasegowda et al. 2015) reported that ADA levels can be used as an indicator to 
predict long term cardiovascular complications in T2DM.  Reduced ADA activity has been 
found in chronic heart failure patients (Khodadadi et al., 2014). Safranow et al. (2007) 
showed that the A allele of the ADA gene can protect against coronary artery disease. 
 Another study conducted on Chinese Han participants showed that another 
polymorphism (rs452159) in the ADA gene is significantly associated with susceptibility to 
chronic heart failure (He et al., 2014).  
In our study, 14.3% of the cases had CVD but no association was found across ADA 
genotypes. These findings are in accordance with a Brazilian study that reported no significant 
differences in allele frequencies between CVD risk in diabetic and control groups (Domingos et 
al., 2014).  
In addition to the small sample size, there are a few limitations in our study, including 
non-estimation of serum insulin levels and homeostasis model of assessment (HOMA-IR), 
which are known to be related to ADA levels. A correlation study between serum ADA level 
and oral glucose tolerance test across ADA genotypes is also needed, which was, however, 
beyond the scope of this study. 
In conclusion, our findings revealed an association of the ADA G22A variant with lower 
levels of FPG and HbA1c in diabetic patients and also point to its association with decreased 
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